The combination of messenger RNA and lipid nanoparticles (mRNA LNPs) represent a novel therapeutic modality with a range of potential applications. However, mRNA is challenged by unavoidably large molecular size, instability, and immunogenicity. Preclinical efforts have shown the utility of LNPs for efficient mRNA encapsulation and tissue-selective delivery. Through advancement in mRNA and lipid chemistry, together with progression in nanoparticle formulation and process science, many barriers were overcome towards robust protein expression in vivo. In addition, more recent evidence has emerged suggesting the ability to encapsulate multiple mRNA cargo within LNPs, enabling the expression and assembly of multi-subunit proteins. The totality of clinical outcomes exemplify progress in the past few years, driving enthusiasm for RNA therapeutics and the area of nanoparticle-mediated oligonucleotide delivery.

Messenger RNA: Delivery challenges and encouraging first steps towards a novel modality

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.